Read More Pharma Industry News Galecto pivots to oncology with Damora Therapeutics buyout and massive $285m funding boost Discover how Galecto’s $285 M Damora Therapeutics acquisition and new mutCALR antibody pipeline could transform myelofibrosis and thrombocythemia treatment. bySoujanya RaviNovember 10, 2025